




SPEAKERS



Steinman is **Professor of Neurology**, Neurological Sciences and Pediatrics at Stanford University and **Chair of the Stanford Program in Immunology** from 2001 to 2011. His research focuses on what provokes relapses and remissions in **MS** and in **NMO** and the quest for **antigen specific therapy**. He is **developing a small molecule therapeutic** in trials for Huntington's Disease. He was **senior author** on the 1992 Nature article that led to the drug **Tysabri**, approved for **MS and Crohn's disease**. Prof. Steinman **holds numerous over 40 patents**. He cofounded several biotech companies. He was a **Director of Centocor** from 1988 until its sale to Johnson and Johnson.

Dr. Pere Santamaria is **Group Leader** in the Institut d'Investigacions Biomediques August Pi i Sunyer in Barcelona (**IDIBAPS**), and **Professor** in the Department of Microbiology, Immunology and Infectious Diseases at the **University of Calgary**. His work focuses on the **immunopathogenesis** of autoimmune disease.



Daniel Benitez is **Doctor in biology** from the University of Barcelona, he is an **expert** in the development of cell therapy based on **dendritic cells** for the treatment of melanoma. Since 2008 he is performing a **clinical study** in patients with Crohn's disease, and currently is working to adapt this **tolerogenic therapeutic** approach and **antigen specific** in patients with **MS**.

Prof. Roland Martin is an **internationally recognized expert** in the fields of **MS** and **neuroimmunology** with a focus on immune function and development of **novel treatments**. He has previously worked at the Universities of Würzburg and Tübingen, Germany, the National Institutes of Health, Bethesda, USA, the Center for Multiple Sclerosis of Catalunya, Barcelona, the University of Hamburg, Germany, and is now at the **University of Zurich Switzerland**.



Dr. Virginia de las Heras has a experience in the San Carlos Clinical Hospital for 11 years, as a resident and **specialist on MS** and she received a Fellowship for her research in this field. Along her period as a **clinical neurologist** has conducted **several local research**, most of them focused on the genetic and the environmental ethiopathogenesis of the MS. Took part in many **international clinical trials as well**. Since 2014 she works in **Novartis Pharma in Spain**, as a Therapeutical Head of Area the Neuroscience Franchise.